TRUTAKNA, a first-in-class dual BAFF and APRIL inhibitor, has shown strong efficacy and safety in IgAN, with significant reductions in proteinuria, Gd-IgA1, and hematuria, and eGFR stabilization. The company is well-funded, holds global rights, and targets a large, underpenetrated market with addit…
TRUTAKNA, a first-in-class dual BAFF and APRIL inhibitor, has shown strong efficacy and safety in IgAN, with significant reductions in proteinuria, Gd-IgA1, and hematuria, and eGFR stabilization. The company is well-funded, holds global rights, and targets a large, underpenetrated market with additional pipeline opportunities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
